Mochi Health vs Noom Med (2026): prices, structure, verdict

On tirzepatide, only Mochi Health↗ has a rankable figure: $278 a month all-in; Noom Med↗ does not offer tirzepatide.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Mochi Health is cheaper: $178 versus $199 a month all-in — a $21 monthly gap, $252 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Mochi Health: the record, condensed

On tirzepatide, the number that matters at Mochi Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Inside that $278 sits a mandatory $79-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $199, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #4 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

Mochi Health’s semaglutide program bills $178 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The all-in figure already contains a compulsory $79 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $99 would be exactly that kind of mirage.

To place the number: #8 of 20 verified programs, with the floor $45/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $171 a month. A year at this figure: $2,136 monthly-billed.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

Noom Med: the record, condensed

Noom Med’s semaglutide program bills $199 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $199 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #12 of 20 verified programs, with the floor $66/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $150 a month. A year at this figure: $2,388 monthly-billed.

Operationally at Noom Med: shipping included; commitment 12-week cycles; cancellation 12-week billing cycles; pharmacy named (Tailor Made Compounding (named)); states: most states; evidence source-verified, captured 2026-08-08. The full record with source and archive links: the Noom Med page · visit Noom Med ↗

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Mochi Health at $178, Noom Med at $199 — a $21 monthly spread that compounds to $252 over a maintenance year and $504 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $21 gap is exactly what it appears to be.

Mochi Health’s total includes a mandatory $79/month membership; Noom Med has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $21/month spread into medication: $252 a year equals roughly 1.4 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Mochi Health $178/mo month-to-month versus Noom Med $199/mo month-to-month. Same winner on both bases — Mochi Health leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Mochi Health $534 monthly; Noom Med $597 monthly — best path favors Mochi Health by $63. 6 months: Mochi Health $1,068 monthly; Noom Med $1,194 monthly — best path favors Mochi Health by $126. 12 months: Mochi Health $2,136 monthly; Noom Med $2,388 monthly — best path favors Mochi Health by $252. 24 months: Mochi Health $4,272 monthly; Noom Med $4,776 monthly — best path favors Mochi Health by $504.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: Mochi Health publishes “most states”; Noom Med publishes “most states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency: both name fulfillment (company-owned compounding facility / Tailor Made Compounding (named)) — rare in this market, and it makes both independently checkable.

Exit terms: Mochi Health — membership recurs monthly; cancel membership any time; recurs until cancelled. Noom Med — 12-week cycles; 12-week billing cycles.

Evidence: Mochi Health source-verified (captured 2026-08-05); Noom Med source-verified (2026-08-08).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full semaglutide index these two sit at #8 and #12 of 20: between them lie 3 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Mochi Health and Noom Med

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Mochi Health: cancel membership any time; recurs until cancelled; Noom Med: 12-week billing cycles) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings